4 assets in Laryngeal Neoplasm

Therapeutic assets addressing Laryngeal Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cobimetinib Laryngeal Neoplasm	Cancer Research UK	P2/3	B (56)
Dabrafenib Laryngeal Neoplasm	Cancer Research UK	P2/3	B (56)
Trametinib Laryngeal Neoplasm	Cancer Research UK	P2/3	B (56)
Vemurafenib Laryngeal Neoplasm	Cancer Research UK	P2/3	CCC (55)